Streetbeat News

IMRX

Immuneering Corporation

Industry

Biotechnology

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Chardan Capital analyst Geulah Livshits maintains a Buy rating on Immuneering (NASDAQ:IMRX) but lowers the price target from $16 to $12.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 11:57 am

Needham analyst Ami Fadia reiterates a Buy rating on Immuneering (NASDAQ:IMRX) and maintains a $15 price target.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 11:46 am

Immuneering (NASDAQ:IMRX) reported a Q2 EPS loss of $(0.47), beating the analyst estimate of $(0.52) by 9.62%. This represents a 9.3% increase in losses compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 9:06 pm

The Nasdaq Composite surged 1% on Thursday, driven by strong earnings from Meta Platforms, Inc. (META). Meta reported better-than-expected Q2 financial results and issued strong Q3 guidance. Other notable stock movements include significant gains for RedHill Biopharma Ltd. (RDHL), Bone Biologics Corporation (BBLG), and Immuneering Corporation (IMRX), while Vintage Wine Estates, Inc. (VWE) saw a sharp decline due to a bankruptcy filing.

Portfolio Pulse from Avi Kapoor

August 01, 2024 | 2:15 pm

Carvana Co. (NYSE:CVNA) shares surged 13.4% in pre-market trading after reporting better-than-expected Q2 financial results. Other notable pre-market movers include FSD Pharma Inc. (NASDAQ:HUGE), Immuneering Corporation (NASDAQ:IMRX), and CareDx, Inc (NASDAQ:CDNA) among gainers, while ALX Oncology Holdings Inc. (NASDAQ:ALXO) and Teladoc Health, Inc. (NYSE:TDOC) were among the losers.

Portfolio Pulse from Avi Kapoor

August 01, 2024 | 12:32 pm

Immuneering shares are trading higher after the company announced that IMM-1-104 was granted Fast Track designation from the FDA.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 11:46 am

Immuneering shares are trading higher after the company announced that IMM-1-104 was granted Fast Track designation from the FDA.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 9:11 pm

Immuneering Corporation (NASDAQ:IMRX) has been granted FDA Fast Track designation for its lead program, IMM-1-104, as a first-line treatment for pancreatic ductal adenocarcinoma (PDAC). This follows a previous Fast Track designation for second-line treatment. The company expects initial data from its Phase 2a trial in the second half of 2024.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 8:59 pm

12 health care stocks experienced significant movements in Tuesday's after-market session. Notable gainers include Autonomix Medical (AMIX), Unicycive Therapeutics (UNCY), and Venus Concept (VERO). Significant losers include Calidi Biotherapeutics (CLDI), BioSig Technologies (BSGM), and ThermoGenesis Holdings (THMO).

Portfolio Pulse from Benzinga Insights

June 11, 2024 | 8:31 pm

Needham analyst Ami Fadia reiterated a Buy rating on Immuneering (NASDAQ:IMRX) and maintained a $15 price target.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 9:58 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.